Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis

Journal of Neuroimmunology

Volumn 256, Issue 1-2, 2013, Pages 62-70

  Annunziata, P ^a   Cioni, C ^a   Cantalupo, L ^a   Di Genova, G ^b   Savellini, G Gori ^b   Cusi, G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Autoimmunity; CD64; Monoclonal antibodies; Multiple sclerosis; Myelin basic protein

Indexed keywords

CD64 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[105-120] ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; COHORT STUDIES; CYTOKINES; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDES; RECEPTORS, IGG; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84875364108     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.12.007     Document Type: Article

References (42)

1. Abdul-Majid K.B., Stefferl A., Bourquin C., Lassmannn H., Linington C., Olsson T., Kleinau S., Harris R.A. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2002, 55:70-81.
2. Annunziata P., Pluchino S., Martino T., Guazzi G. High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis. J. Neuroimmunol. 1997, 77:128-133.
3. Breij E.C.W., Heijnen P., Vloet R., Saito T., van de Winkel J.G., Dijkstra C.D., Amor S., Verbeek S. The FcRγ chain is not essential for induction of experimental allergic encephalomyelitis (EAE) or anti-myelin antibody-mediated exacerbation of EAE. J. Neuropathol. Exp. Neurol. 2005, 64:304-311.
4. Burns J., Rosenzweig A., Zweiman B., Lisak R.P. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell. Immunol. 1983, 77:363-371.
5. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
6. De Jong B.A., Schrijver H.M., Hiuzinga T.W.J., Bollen E.L.E.M., Polman C.H., Uitdehaag B.M.G., Kersbergen M.C., Sturk A., Westendorp R.G. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann. Neurol. 2000, 48:641-646.
7. Gerber J.S., Mosser D.M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors. J. Immunol. 2001, 166:6861-6868.
8. Gonsette R.E. Introductory remarks: immunosuppressive and immunomodulating drugs, where and how do they act?. Mult. Scler. 1996, 1:306-312.
9. Greer J.M., Csurshes P.A., Cameron K.D., McCombe P.A., Good M.F., Pender M.P. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiplesclerosis. Brain 1997, 20:1447-1460.
10. Hawkins S.A., McDonnell G.V. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J. Neurol. Neurosurg. Psychiatry 1999, 67:148-152.
11. Hussain R.F., Nouri A.M., Oliver R.T. A new approach for measurement of cytotoxicity using colorimetric assay. J. Immunol. Methods 1993, 160:89-96.
12. Hutchinson M. Disability due to multiple sclerosis: a community-based study of an Irish country. Ir. Med. J. 1986, 79:48-50.
13. Jingwu Z., Henderikx P., Ying C., Medaer R., Raus J.C.M. A method to establish antibody secreting B cell lines and simultaneously perform frequency analysis. J. Immunol. Methods 1989, 123:153-154.
14. Jingwu Z., Vandenbark A.A., Jacobs M.P., Medaer R., Raus J.C.M. Murine monoclonal anti-myelin basic protein (MBP) antibodies inhibit proliferation and cytotoxicity of MBP-specific human T cell clones. J. Neuroimmunol. 1989, 24:87-94.
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983, 33:1444-1452.
16. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122:2089-3100.
17. Linington C., Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 1987, 17:61-69.
18. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
19. Lutz H.U. Homeostatic roles of naturally occurring antibodies: an overview. J. Autoimmun. 2007, 29:287-294.
20. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
21. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59:880-892.
22. 2B receptor-mediated posttranscriptional mechanism. J. Immunol. 2005, 175:8260-8270.
23. Olsson T., Baig S., Hojeberg B., Link H. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann. Neurol. 1990, 27:132-136.
24. Ota K., Matsui M., Milford E., Mackin G.A., Weiner H.L., Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346:183-187.
25. Poser S., Wikstrom J., Bauer H.J. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J. Neurol. Sci. 1979, 40:159-168.
26. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley V.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
27. Poser S., Poser W., Schlaf G., Firnhaber W., Lauer K., Wolter M., et al. Prognostic indicators in multiple sclerosis. Acta Neurol. Scand. 1986, 74:387-392.
28. Raine C.S., Johnson A.B., Marcus D.M., Suzuki A., Bornstein M.B. Demyelination in vitro. Absorption studies demonstrate that galactocerebroside is a major target. J. Neurol. Sci. 1981, 52:117-131.
29. Rodriguez M., Warrington A.E., Pease L.R. Human natural autoantibodies in the treatment of neurologic disease. Neurology 2009, 72:1269-1276.
30. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up. Brain 1993, 116:117-134.
31. Sutterwala F.S., Noel G.J., Salgame P., Mosser D.M. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. J. Exp. Med. 1998, 188:217-222.
32. Thompson A., Hutchinson M., Brazil J., Feighery C., Martin E.A. A clinical and laboratory study of benign multiple sclerosis. QJM 1986, 225:69-80.
33. Ulvestad E., Williams K., Matre R., Nyland H., Olivier A., Antel J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J. Neuropathol. Exp. Neurol. 1994, 53:27-36.
34. Van Boxel-Dezaire A.H.H., van Oosten B.W., Verweij Drager A.M., Verweij C.L., Drager A.M., Ader H.G., van Houwelingen J.C., Barkhof F., Polman C.H., Nagelkerken L. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 1999, 45:695-703.
35. Van de Winkel J.G.J., Capel P.J.A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993, 14:215-221.
36. Vedeler C.A., Myhr K.-M., Nyland H. Fc receptors for immunoglobulin G - a role in the pathogenesis of Guillain-Barré syndrome and multiple sclerosis. J. Neuroimmunol. 2001, 118:187-193.
37. Visscher B., Liu K.-S., Clark V.A., Detels R., Malmgren R.M., Dudley J.P. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol. Scand. 1984, 70:321-328.
38. Wandinger K.-P., Jabs W., Siekhaus A., Bubel S., Trillenberg P., Wagner H.J., et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000, 55:178-184.
39. Warren K.G., Catz I. Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. J. Neuroimmunol. 1992, 39:81-90.
40. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and model of outcome. Brain 1991, 114:1045-1056.
41. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
42. Wucherpfennig K.W., Catz I., Hausmann S., Strominger J.L., Steinman L., Warren K.G. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 1997, 100:1114-1122.